<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 8</script></head><body class="s8"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence active"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.go(12)" class="page-next"></div><div onclick="iRep.go(6)" class="page-prev"></div></div><article><div class="panel1"><h3>Rivaroxaban 15mg o.d.: bleeding outcomes<sup>1,2</sup></h3><div class="labels"><div onclick="iRep.go(6)" class="label"><div class="text">PRADAXA<sup>®</sup> 110mg</div></div><div onclick="iRep.go(7)" class="label"><div class="text">APIXABAN <br/>2.5mg</div></div><div class="label next-panel"><div class="text">RIVAROXABAN <br/> 15 & 20mg</div></div></div><div class="down-bar"></div><div class="hr-text">HR: 0.95 (0.72–1.26)</div><div class="graph"><div class="chart"><div class="title">Rivaroxaban 15mg o.d.</div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.17% ARR<br/>19% RRR<br><span>(p=ns)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.21% ARR<br/>5% RRR<br/><span>(p=ns)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">1.11% ARI<br/>63% RRI</div></div></div></div><div class="chart2"><div class="title">Pradaxa<sup>®</sup> 110mg b.d.<sup>4-6</sup></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.53% ARR<br/>70% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.69% ARR<br/>20% RRR<br/><span>(p=0.003)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">0.08% ARI<br/>8% RRI<br/><span>(p=ns)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div><div class="note">Please note that these data are not from a head-to-head trial</div></div></div><div class="panel2 hide"><h3>Rivaroxaban 15mg and 20mg o.d.: bleeding outcomes<sup>1,3</sup></h3><div class="labels"><div onclick="iRep.go(6)" class="label"><div class="text">PRADAXA<sup>®</sup> 110mg</div></div><div onclick="iRep.go(7)" class="label"><div class="text">APIXABAN <br/>2.5mg</div></div><div class="label prev-panel"><div class="text">RIVAROXABAN <br/> 15mg</div></div></div><div class="down-bar"></div><div class="graph"><div class="chart"><div class="title"></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.20% ARR<br/>33% RRR<br/><span>(p=0.02)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.20% ARI<br/>4% RRI<br/><span>(p=ns)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">0.76% ARI<br/>66% RRI<br/><span>(p<0.0001)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div></div></div></article><div class="overlay"></div><div class="sidebar"><ul><li class="brain-tab tab"></li><li class="warfarin-tab tab"></li><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"><b>References: 1.</b> Patel MR,<em> et al. N Engl J Med</em> 2011; 365:883–91.<b> 2.</b> Fox KAA,<em> et al. Eur Heart J</em> 2011; 32:2387–94.<b> 3.</b> Sherwood MW,<em> et al. J Am Coll Cardiol</em> 2015;66(21):2271–81.<b> 4.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2009; 361:1139–51.<b> 5.</b> Connolly SJ<em> et al. N Engl J Med</em> 2010; 363:1875–6.<b> 6.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2014; 371:1464–5.<b> 7.</b> Boehringer Ingelheim. Pradaxa<sup>&reg;</sup> 110mg hard capsules Summary of Product Characteristics.<b> 8.</b> Bayer. Xarelto<sup>&reg;</sup> 15mg film coated tablets Summary of Product characteristics.</div></div><div class="content warfarin"><img src="img/s08/popup.png"></div><div class="content brain"><h3 class="title-popup">Rivaroxaban 15mg o.d.: stroke outcomes<sup>2</sup></h3><div class="down-bar"></div><div class="graph"><div class="chart"><div class="title-graph">Rivaroxaban 15mg o.d.</div><div class="bars"><div class="title1">ISCHAEMIC</div><div class="bar bar1"><div class="text">0.20% ARI<br>11% RRI</div></div></div><div class="bars"><div class="title1">HAEMORR-<br/>HAGIC</div><div class="bar bar2"><div class="text">0.23% ARR<br>44% RRR</div></div></div><div class="bars"><div class="title1">STROKE/</br>SYSTEMIC<br/>EMBOLISM</div><div class="bar last bar3"><div class="text">0.45% ARR<br/>16% RRR</div></div></div><div class="subnote note1">HR 1.11 (0.71–1.73)</div><div class="subnote note2">HR 0.56 (0.21–1.51)</div><div class="subnote note3">HR 0.84 (0.57–1.23)</div></div><div class="chart2"><div class="title-graph">Pradaxa<sup>®</sup> 110mg b.d.<sup>4–6,7</sup></div><div class="bars"><div class="title1">ISCHAEMIC</div><div class="bar bar1"><div class="text">0.14% ARI<br/>13% RRI<br/><span>(p=ns)</span></div></div></div><div class="bars"><div class="title1">HAEMORR-<br/>HAGIC</div><div class="bar bar2"><div class="text">0.26% ARR<br/>69% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><div class="title1">STROKE/</br>SYSTEMIC<br/>EMBOLISM</div><div class="bar last bar3"><div class="text">0.18% ARR<br/>11% RRR<br/><span>(p=ns)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div><div class="note">Please note that these data are not from a head-to-head trial</div></div></div></div></div></div></body></html>